MSAFP


Also found in: Acronyms.

MSAFP

abbreviation for maternal serum alpha-fetoprotein. See maternal serum alpha-fetoprotein (MSAFP) test.

MSAFP

maternal serum alpha-fetoprotein.
References in periodicals archive ?
The coincide increase of acetylcholine-esterase and MSAFP is the marker of defeet in nervous tube.
Elevated MSAFP and low MSuE3 concentrations are highly predictive for neural tube defects.
Among the 334 women who actually had a second MSAFP assay, 150 had a second sample less than 2.
Levels of four serum markers - inhibin A, MSAFP, HCG, and unconjugated estriol (uE3) - were analyzed alone and in selected combinations for their association with stillbirth.
Other conditions that may elevate MSAFP include underestimation of gestational age, multiple gestation pregnancies (twins or more), racial origin, placental changes, fetal abdominal wall defects, congenital nephrosis, fetal death, polycystic kidneys, and low birth weight.
Eighty-seven percent of the physicians offered MSAFP testing, most of them routinely, However, relatively few patients chose to have the test done.
MSAFP, a maternal blood draw that screens for neural tube defects (serious anomalies of the fetal brain and spine), represents the new prenatal screening: procedurally simple, inexpensive, and noninvasive procedures that can be offered to all pregnant women.
From a technical vantage, MSAFP testing is straightforward and can be performed by any laboratory with experience in radioimmunoassay or enzyme immunoassay methods.
Screening using a combination of maternal age, MSAFP, and maternal serum free [beta]-human chorionic gonadotropin ([beta]-hCG) or total hCG has enabled trisomy 21 detection rates of 65-70% (for a 5% screen-positive rate) to be achieved in second-trimester prospective screening (2, 3).
In addition to MSAFP, for example, routine prenatal screening includes testing for toxoplasmosis, an infectious disease with no known genetic component.
The third case described what was in 1985 a new, controversial interpretation linking low MSAFP with Down syndrome.
In California, where mandatory offering of MSAFP screening has been in effect since the spring of 1986, or about 50 percent of all pregnancies have actually been screened during the second trimester.